---
title: "FDA clears Roche’s giredestrant; semaglutide shows efficacy in children with severe obesity"
id: "stat-news-4-stat-pharmalittle-we-re-reading-about-a-roche-breast-cancer-pill-obesity-drugs"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-roche-breast-cancer-pill-obesity-drugs"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss"
published_at: "2026-11-17T14:25:41.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA clears Roche’s giredestrant; semaglutide shows efficacy in children with severe obesity
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-roche-breast-cancer-pill-obesity-drugs
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss)
- **Published At:** 2026-11-17T14:25:41.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The U.S. Food and Drug Administration approved Roche’s oral breast cancer agent **giredestrant**, a regulatory milestone the company had been awaiting and one that Roche believes could become a major product. - Analysts projected that giredestrant might reach multibillion-dollar sales if it secures approvals in other breast cancer indications; the source reported this market potential but did not provide specific sales forecasts or modeled assumptions. - A clinical trial presented at Obesity Week tested **semaglutide** in children ages 6–11 with mostly severe **obesity** (body mass index ≥35 in most participants), and findings showed marked weight-status improvement by week 68. - After 68 weeks, nearly 40% of children receiving semaglutide no longer met obesity criteria; none in the placebo group achieved that outcome, according to the trial results reported in the source. - The article noted that some clinicians expressed concern about prescribing weight-loss medications to very young patients; the source did not report detailed safety data, adverse-event rates, or long-term follow-up beyond 68 weeks. - The STAT piece emphasized Roche’s oncology history (including Herceptin via Genentech) and that the new approval gives the company an expanded presence in breast cancer, while also noting it has lagged rivals in recent years. - The source did not report trial sample sizes, p-values, dosing regimens, patient demographics beyond age and BMI category, or other detailed methodology for either the giredestrant approval or the pediatric semaglutide trial. - Key open questions from the source include whether giredestrant will gain additional indications and what safety and prescribing approaches clinicians will adopt for GLP-1 use in young children; regulatory next steps for broader approvals were mentioned but not specified in detail.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss) [education](https://www.statnews.com/topic/education/) [research](https://www.statnews.com/topic/research/) [FDA](https://www.statnews.com/topic/fda/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) China's Biotech Powerhouse 25 We ranked the 25 most valuable publicly traded Chinese drugmakers [ See the list ](https://www.statnews.com/china-biotech-index-powerhouse-25/) [STAT Plus](https://www.statnews.com/stat-plus/)Newsletter[Pharmalot](https://www.statnews.com/category/pharma/pharmalot/) # Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more ## Newer GLP-1 drugs to combat obesity may be the next global battleground over access * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/?utm_campaign=rss) ![an anthropomorphized red and blue pill illustrated in the style of the famous american gothic painting](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg) Alex Hogan/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Nov. 17, 2026 Pharmalot Columnist, Senior Writer ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") 2. [](https://x.com/Pharmalot "X") ed.silverman@statnews.com Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they are happily snoozing in their respective corners. As for us, we are firing up the trusty kettle for another cup of stimulation. Our choice today is pumpkin spice, which remains a seasonal favorite. Of course, you are invited to join us. For the full experience, we are still hawking replicas — [take a look](https://store.bostonglobe.com/collections/stat-news/products/pharmalot-mug). Meanwhile, here are a few items of interest. As always, do keep in touch. We appreciate feedback, criticism, and tips. … **The U.S. Food and Drug Administration approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the company has said could become its top-selling product ever** , [STAT](https://www.statnews.com/2026/11/16/fda-approves-new-roche-breast-cancer-drug/) says. The approval for the drug, known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its Genentech subsidiary, though in recent years it has fallen behind rivals in oncology. Analysts broadly see giredestrant becoming a multibillion-dollar blockbuster if Roche wins approval in other forms of breast cancer. Advertisement **New results from a closely watched clinical trial showed that weight loss drugs are effective for children as young as 6, though some doctors say they are concerned about the prospect of prescribing these medications to such young patients** , [The New York Times](https://www.nytimes.com/2026/11/16/well/weight-loss-drugs-children.html) writes. The study, presented at the medical conference Obesity Week, examined children ages 6 to 11 who were taking semaglutide, the compound in Ozempic and Wegovy. Most children in the trial had severe obesity, meaning they had a body mass index of 35 or higher. After 68 weeks, nearly 40% of those who took the drug no longer had obesity, compared with none of the patients on a placebo. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [pharmalittle](https://www.statnews.com/topic/pharmalittle/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Pharmalot Columnist, Senior Writer 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2022/12/19467-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial](https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_331634765-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After death in gene therapy trial for a brain disease, progress is reported ](https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/) 3. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_587333568_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In a win for MAHA, FDA creates new regulatory category for the supplement NAC](https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/) 5. ![](https://www.statnews.com/wp-content/uploads/2019/05/AP_19100658378432-80x80.jpg) [Faith-based addiction recovery groups don’t often get federal funding. RFK Jr. wants to change that](https://www.statnews.com/2026/11/17/rfk-jr-federal-funding-faith-based-recovery-groups/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_391451620_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_6400491-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA warns GLP-1 drugs carry potential risk of rare eye condition](https://www.statnews.com/2026/11/09/glp-1-drugs-potential-risk-rare-eye-condition-naion-fda/) 3. ![](https://www.statnews.com/wp-content/uploads/2019/09/AP_060324030695-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves novel Bayer drug to reduce recurrence of stroke](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/) 4. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 5. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns ](https://www.statnews.com/pharmalot/2026/11/16/semaglutide-obesity-glp1-access-medicines-low-income-countries/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more ](https://www.statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return-on-investment/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 13, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Up and down the ladder: The latest comings and goings ](https://www.statnews.com/pharmalot/2026/11/13/up-down-ladder-jobs-pharma-biotech-2/) By [Ed Silverman](https:
## Related Clinical Research

- [Retatrutide: A New Approach for Easing Knee Osteoarthritis Pain](https://medichelpline.com/clinical-feed/medical-news-today-0-new-weight-loss-drug-eases-knee-osteoarthritis-pain-in-major-trials.md)
- [Retatrutide and obstructive sleep apnea: phase 3 trials show AHI improvements](https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea.md)
- [FDA approves Roche’s Wilserdly (giredestrant) for ESR1-mutant HR-positive, HER2-negative breast ca](https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-approves-new-breast-cancer-drug-providing-new-option-for-some-patients.md)
- [Global access clash looms for newer GLP-1 obesity drugs, expert warns](https://medichelpline.com/clinical-feed/stat-news-3-stat-expert-warns-of-battleground-over-global-access-to-newer-glp-1-drugs-for.md)
- [GLP-1 receptor agonist weight loss in breast cancer patients on endocrine therapy](https://medichelpline.com/clinical-feed/pubmed-42932003.md) (DOI: 10.1007/s10549-026-08096-z)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.